This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cowsert, L M Articles by Mirabelli, C K Search for Related Content PubMed PubMed Citation Articles by Cowsert, L M Articles by Mirabelli, C K

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1993 February; 37(2): 171-177

In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts.

ISIS Pharmaceuticals, Carlsbad, California 92008.

ABSTRACT

Papillomaviruses induce benign proliferative lesions, such as genital warts, in humans. The E2 gene product is thought to play a major role in the regulation of viral transcription and DNA replication and may represent a rational target for an antisense oligonucleotide drug action. Phosphorothioate oligonucleotides complementary to E2 mRNAs were synthesized and tested in a series of in vitro bovine papillomavirus (BPV) and human papillomavirus (HPV) models for the ability to inhibit E2 transactivation and virus-induced focus formation. The most active BPV-specific compounds were complementary to the mRNA cap region (ISIS 1751), the translation initiation region for the full-length E2 transactivator (ISIS 1753), and the translation initiation region for the E2 transrepressor mRNA (ISIS 1755). ISIS 1751 and ISIS 1753 were found to reduce E2-dependent transactivation and viral focus formation in a sequence-specific and concentration-dependent manner. ISIS 1755 increased E2 transactivation in a dose-dependent manner but had no effect on focus formation. Oligonucleotides with a chain length of 20 residues had optimal activity in the E2 transactivation assay. On the basis of the above observations, ISIS 2105, a 20-residue phosphorothioate oligonucleotide targeted to the translation initiation of both HPV type 6 (HPV-6) and HPV-11 E2 mRNA, was designed and shown to inhibit E2-dependent transactivation by HPV-11 E2 expressed from a surrogate promoter. These observations support the rationale of E2 as a target for antiviral therapy against papillomavirus infections and specifically identify ISIS 2105 as a candidate antisense oligonucleotide for the treatment of genital warts induced by HPV-6 and HPV-11.

This article has been cited by other articles:

• Deng, S.-J., Pearce, K. H., Dixon, E. P., Hartley, K. A., Stanley, T. B., Lobe, D. C., Garvey, E. P., Kost, T. A., Petty, R. L., Rocque, W. J., Alexander, K. A., Underwood, M. R. (2004). Identification of Peptides That Inhibit the DNA Binding, trans-Activator, and DNA Replication Functions of the Human Papillomavirus Type 11 E2 Protein. J. Virol. 78: 2637-2641 [Abstract] [Full Text]  
• Stanley, M. (2003). Chapter 17: Genital Human Papillomavirus Infections--Current and Prospective Therapies. J Natl Cancer Inst Monogr 2003: 117-124 [Abstract] [Full Text]  
• Bunnell, B. A., Morgan, R. A. (1998). Gene Therapy for Infectious Diseases. Clin. Microbiol. Rev. 11: 42-56 [Abstract] [Full Text]  
• Phillips, M. I. (1997). Antisense Inhibition and Adeno-Associated Viral Vector Delivery for Reducing Hypertension. Hypertension 29: 177-187 [Abstract] [Full Text]  
• Condon, T. P., Bennett, C. F. (1996). Altered mRNA Splicing and Inhibition of Human E-selectin Expression by an Antisense Oligonucleotide in Human Umbilical Vein Endothelial Cells. J. Biol. Chem. 271: 30398-30403 [Abstract] [Full Text]  
• Fennewald, S. M., Rando, R. F. (1995). Inhibition of High Affinity Basic Fibroblast Growth Factor Binding by Oligonucleotides. J. Biol. Chem. 270: 21718-21721 [Abstract] [Full Text]